FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3161299017> ?p ?o ?g. }

• W3161299017 abstract "Serous ovarian cancer (SOC) is a highly lethal gynecological malignancy with poor prognosis. Given the importance of the immune-related tumor microenvironment (TME) in ovarian cancer, investigating tumor-immune interactions and identifying novel prognostic and therapeutic targets in SOC is a promising avenue of research. ALOX5AP (Arachidonate 5-Lipoxygenase Activating Protein) is a key enzyme in converting arachidonic acid to leukotriene: a crucial immune-modulating lipid mediator. However, the role of ALOX5AP in SOC has yet to be studied.ALOX5AP expression patterns across ovarian cancer and their normal tissue counterparts were cross-checked using public microarray and RNA-seq analyses and then validated in clinical samples by qRT-PCR. Kaplan-Meier survival analysis was performed in multiple independent SOC patient cohorts. Univariate and multivariate Cox regression analysis were then employed to identify clinical risk parameters associated with survival, and a genomic-clinicopathologic nomogram was built. Gene enrichment, immune infiltration, and immunosuppressor correlation analyses were then evaluated.ALOX5AP mRNA levels in SOC tissues were significantly upregulated compared to normal tissues. Elevated ALOX5AP was markedly associated with poor overall survival and progression-free survival in multiple SOC patient cohorts as well as with adverse clinicopathological features, including lymphatic invasion, unsatisfactory cytoreductive surgery, rapid relapse after primary treatment, and platinum non-responsiveness. A predictive nomogram, which integrated ALOX5AP expression and two independent prognosis factors (primary therapy outcome and tumor residual), was conducted to predict the 3-year and 5-year survival rate of SOC patients. Mechanistically, functional and pathway enrichment analyses revealed that ALOX5AP was primarily involved in immune response and regulation. Further exploration demonstrated that ALOX5AP was highly expressed in the immunoreactive subtype of ovarian cancer and closely related to immunocyte infiltration, especially M2 macrophage polarization. Additionally, ALOX5AP was enriched in the C4 (lymphocyte depleted) immune subtype of SOC and associated with crucial immune-repressive receptors in the tumor microenvironment at the genomic level.ALOX5AP expression indicates a worse survival outcome and has the potential to be utilized as a prognostic predictor for SOC patients. Given the availability of well-studied ALOX5AP inhibitors, this study has immediate clinical implications for the exploitation of ALOX5AP as an immunotherapeutic target in SOC." @default.
• W3161299017 created "2021-05-24" @default.
• W3161299017 creator A5025855204 @default.
• W3161299017 creator A5027990152 @default.
• W3161299017 creator A5028449710 @default.
• W3161299017 creator A5047146848 @default.
• W3161299017 creator A5047747533 @default.
• W3161299017 creator A5054109702 @default.
• W3161299017 creator A5054175979 @default.
• W3161299017 creator A5056000409 @default.
• W3161299017 creator A5066320639 @default.
• W3161299017 creator A5070157648 @default.
• W3161299017 date "2021-05-19" @default.
• W3161299017 modified "2023-10-02" @default.
• W3161299017 title "ALOX5AP Predicts Poor Prognosis by Enhancing M2 Macrophages Polarization and Immunosuppression in Serous Ovarian Cancer Microenvironment" @default.
• W3161299017 cites W1066986691 @default.
• W3161299017 cites W1506578309 @default.
• W3161299017 cites W1520264805 @default.
• W3161299017 cites W1966107523 @default.
• W3161299017 cites W1975543140 @default.
• W3161299017 cites W2006617902 @default.
• W3161299017 cites W2030610701 @default.
• W3161299017 cites W2033242554 @default.
• W3161299017 cites W2035618305 @default.
• W3161299017 cites W2041143310 @default.
• W3161299017 cites W2056950140 @default.
• W3161299017 cites W2057133574 @default.
• W3161299017 cites W2061453728 @default.
• W3161299017 cites W2076124116 @default.
• W3161299017 cites W2094003769 @default.
• W3161299017 cites W2100876968 @default.
• W3161299017 cites W2102004732 @default.
• W3161299017 cites W2123106337 @default.
• W3161299017 cites W2130410032 @default.
• W3161299017 cites W2138644182 @default.
• W3161299017 cites W2143017330 @default.
• W3161299017 cites W2159707944 @default.
• W3161299017 cites W2171814332 @default.
• W3161299017 cites W2179438025 @default.
• W3161299017 cites W2438866487 @default.
• W3161299017 cites W2529727810 @default.
• W3161299017 cites W2582623762 @default.
• W3161299017 cites W2597754568 @default.
• W3161299017 cites W2725375820 @default.
• W3161299017 cites W2734973925 @default.
• W3161299017 cites W2737592678 @default.
• W3161299017 cites W2738732235 @default.
• W3161299017 cites W2741508285 @default.
• W3161299017 cites W2795989238 @default.
• W3161299017 cites W2796207838 @default.
• W3161299017 cites W2797580541 @default.
• W3161299017 cites W2801309958 @default.
• W3161299017 cites W2805395855 @default.
• W3161299017 cites W2807649309 @default.
• W3161299017 cites W2810811103 @default.
• W3161299017 cites W2846183811 @default.
• W3161299017 cites W2910301764 @default.
• W3161299017 cites W2921858013 @default.
• W3161299017 cites W2922640443 @default.
• W3161299017 cites W2928665623 @default.
• W3161299017 cites W2937441321 @default.
• W3161299017 cites W2939093246 @default.
• W3161299017 cites W2946657092 @default.
• W3161299017 cites W2947142752 @default.
• W3161299017 cites W2948559837 @default.
• W3161299017 cites W2949439905 @default.
• W3161299017 cites W2956024695 @default.
• W3161299017 cites W2993109673 @default.
• W3161299017 cites W2994532040 @default.
• W3161299017 cites W2998015544 @default.
• W3161299017 cites W3002671092 @default.
• W3161299017 cites W3013416758 @default.
• W3161299017 cites W3014441882 @default.
• W3161299017 cites W3022344729 @default.
• W3161299017 cites W3022854879 @default.
• W3161299017 cites W3024099774 @default.
• W3161299017 cites W3026733592 @default.
• W3161299017 cites W3027286012 @default.
• W3161299017 cites W3050006971 @default.
• W3161299017 cites W3096914895 @default.
• W3161299017 cites W3102568044 @default.
• W3161299017 cites W3103119004 @default.
• W3161299017 cites W3119005666 @default.
• W3161299017 cites W3135882325 @default.
• W3161299017 cites W3191661929 @default.
• W3161299017 doi "https://doi.org/10.3389/fonc.2021.675104" @default.
• W3161299017 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8172172" @default.
• W3161299017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34094977" @default.
• W3161299017 hasPublicationYear "2021" @default.
• W3161299017 type Work @default.
• W3161299017 sameAs 3161299017 @default.
• W3161299017 citedByCount "12" @default.
• W3161299017 countsByYear W31612990172022 @default.
• W3161299017 countsByYear W31612990172023 @default.
• W3161299017 crossrefType "journal-article" @default.
• W3161299017 hasAuthorship W3161299017A5025855204 @default.
• W3161299017 hasAuthorship W3161299017A5027990152 @default.
• W3161299017 hasAuthorship W3161299017A5028449710 @default.
• W3161299017 hasAuthorship W3161299017A5047146848 @default.
• W3161299017 hasAuthorship W3161299017A5047747533 @default.

• next